Clinical Trial Update: Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders [Phase 1, Phase 2]

View source ↗

Summary

The document notes the completion of a Phase 1/2 clinical trial evaluating tipifarnib in patients with chronic myeloid leukemia, chronic myelomonocytic leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasm Unclassifiable
• Myelomonocytic Leukemia

Drugs mentioned

• Tipifarnib (tipifarnib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Accelerated Phase of Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Phase 1, Phase 2 | Status: COMPLETED